Bispecific antibody combo outperforms standard care in follicular lymphoma trial

A major phase 3 trial is reshaping the treatment landscape for relapsed or refractory (R/R) follicular lymphoma (FL). The CELESTIMO trial found that mosunetuzumab (Lunsumio) combined with lenalidomide significantly improved progression-free survival (PFS) compared to the current standard of rituximab plus lenalidomide in patients who had received at least one prior line of therapy.

Mosunetuzumab is a CD20xCD3 T-cell-engaging bispecific antibody already approved for R/R FL after two or more prior lines of treatment. These new results suggest it could be effective even earlier in the treatment journey — potentially as a second-line option — and as a convenient outpatient regimen.

Key Takeaways:

• The CELESTIMO trial met its primary endpoint of improved PFS vs. rituximab + lenalidomide
• Overall survival data remain immature at this stage
• Results will be submitted to regulators to convert the current accelerated approval to full traditional approval and to secure a new second-line indication

Why it matters: Follicular lymphoma is the most common indolent B-cell lymphoma, and patients often face multiple relapses. An effective, outpatient bispecific antibody regimen that works earlier in the disease course could meaningfully improve outcomes and quality of life for this population.